Review
Copyright ©The Author(s) 2023.
World J Gastroenterol. May 7, 2023; 29(17): 2515-2533
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2515
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Proposed design of circulating tumor DNA-guided treatment strategy in gastric cancer. Schematic presentation of proposed circulating tumor DNA (ctDNA) guided treatment strategy in gastric cancer evaluating tailored treatment based on ctDNA detection. ctDNA positivity was determined by accessing the presence of plasma mutations, which indicates the existence of minimal residual disease. Adapted from Chakrabarti et al[100], and Kasi et al[101]. ctDNA: Circulating tumor DNA; Op: Operative; Adj: Ajuvant chemotherapy.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 The summary of non-coding RNAs as biomarker for early detection of gastric cancer. Schematic of the non-coding RNAs composition. Liquid biopsy obtained from peripheral blood is composed of different tumoral components such as micro-RNA, long non-coding RNAs, and circular RNAs. miRNA: MicroRNA; lncRNA: Long non-coding RNA; circRNA: Circular RNA; piRNA: Piwi-interacting RNAs.